Product Usage: For Research Use Only – Not for Human or Veterinary Use

This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. It is strictly intended for in vitro research by qualified professionals. Any use in humans or animals is strictly prohibited and may violate federal, state, or local laws, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic application is implied or permitted. The purchaser assumes all responsibility for compliance with applicable regulations.

Semax / Selank research vial

Semax / Selank – 10mg / 10mg

Semax / Selank (10mg / 10mg) is a lyophilized research blend pairing two well-characterized Russian-developed neuropeptides. Semax and Selank have each been studied independently in published research for their relevance to neurotrophic signaling (BDNF/NGF), stress-response and anxiety-related models, and cognitive-performance measures in tested animal and clinical study populations. Supplied at research-grade purity for laboratory use only.

$175.00

Researchers who buy this Semax / Selank research peptide blend are typically studying two structurally related Russian-developed heptapeptides — Semax, derived from ACTH(4-10) and studied primarily for BDNF/neurotrophin signaling, and Selank, derived from tuftsin and studied primarily for GABA-A-mediated anxiolytic activity — supplied together in a single fixed-ratio preparation. The summary below reflects the published preclinical and clinical literature on each component and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

Buy Semax Selank blend research peptide 10mg 10mg vial by First Class Science

In this reference:

What Is This Blend?

This vial supplies a fixed-ratio, 10mg/10mg lyophilized combination of two structurally related Russian-developed heptapeptides, both extended with a stabilizing Pro-Gly-Pro tripeptide sequence but derived from different parent hormones and studied for different primary research mechanisms. Semax is derived from ACTH(4-10); Selank is derived from tuftsin, a tetrapeptide fragment of immunoglobulin G. Both compounds carry a regulatory history in Russia distinct from Western (FDA/EMA) drug-approval standards, detailed on each compound’s own dedicated page.

Semax: Mechanism and Research

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is studied primarily for its association with brain-derived neurotrophic factor (BDNF) gene expression. A single intranasal application in rats was reported to produce rapid neurotrophin gene-expression changes, including a maximal 1.4-fold increase in BDNF protein levels in specific rat brain regions (Dmitrieva VG, et al., Dokl Biol Sci. 2003;391:292-5; PMID 14556513). A full literature review, including Semax’s Russian regulatory history and clinical research record, is available on its own dedicated page: Semax – 10mg.

Selank: Mechanism and Research

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is studied primarily for anxiolytic-like activity, with published research proposing allosteric modulation at the GABA-A receptor as the primary mechanism, alongside documented effects on hippocampal BDNF expression and immune/cytokine gene expression. A full literature review, including the two published Russian clinical trials comparing Selank against benzodiazepine comparators, is available on its own dedicated page: Selank – 10mg.

Why Researchers Study This Combination

Because Semax and Selank are structurally related (both extended with the same stabilizing Pro-Gly-Pro sequence) but are studied for distinct primary mechanisms — BDNF/neurotrophin signaling for Semax, GABA-A-mediated anxiolytic activity for Selank — researchers combine them to model potential complementary nootropic and anxiolytic-pathway research protocols in a single preparation. No published research has evaluated this specific fixed-ratio combination directly; the citations above and on each compound’s own page describe the individual compounds.

Chemical Identity

Component 1 Semax — 10mg
Component 2 Selank — 10mg
Semax MW ~813.9 g/mol
Selank MW ~751.9 g/mol
Appearance White to off-white lyophilized powder

Purity, Storage & Quality

First Class Science supplies this Semax / Selank blend at research-grade purity, with each component independently verified by third-party HPLC testing and mass spectrometry prior to blending. A Certificate of Analysis is available for every batch at our Certificate of Analysis page.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Related Single-Compound Preparations

Laboratories designing protocols that isolate a single mechanism typically select the standalone Semax or Selank vial.

Frequently Asked Questions

What is the purity of this blend?
Each component is independently verified via third-party HPLC and mass-spectrometry testing prior to blending, with a Certificate of Analysis published for each lot.

How should this Semax / Selank blend be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is this blend approved for human or animal use?
No. Neither Semax nor Selank is an FDA-approved drug for any indication under Western regulatory standards. Both are Russian-registered/researched compounds with a distinct regulatory history detailed on each compound’s own page. This product is sold exclusively for in vitro and laboratory research use.

Why are these two specific compounds combined?
Semax and Selank share a structural stabilizing motif (Pro-Gly-Pro) but are studied for distinct primary mechanisms — BDNF/neurotrophin signaling and GABA-A-mediated anxiolytic activity, respectively. Researchers combine them to model potential complementary nootropic/anxiolytic research protocols.

Has either compound been tested in humans?
Yes, independently, in Russia under Russian regulatory and publication standards. See each compound’s own product page for the full published clinical-research record. Neither trial evaluated this specific fixed-ratio combination.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date for each component.

Shipping, Handling & Compliance

This blend ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal or clinical contexts under varying regulatory standards, examining each individual compound. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal. No published research has evaluated this specific fixed-ratio combination directly.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.